[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Tsukamoto et al., 2011 - Google Patents

Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1

Tsukamoto et al., 2011

View PDF
Document ID
599339404112969204
Author
Tsukamoto M
Hiroi S
Adachi K
Kato H
Inai M
Konishi I
Tanaka M
Yamamoto R
Sawa M
Handharyani E
Tsukamoto Y
Publication year
Publication venue
Molecular medicine reports

External Links

Snippet

The most effective method for the prevention of influenza infection would be prophylaxis with a safe and effective vaccine and anti-viral materials. After vaccination, neutralizing antibodies are generated by plasma cells following various immune responses, thus …
Continue reading at www.spandidos-publications.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Similar Documents

Publication Publication Date Title
Tsukamoto et al. Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1
JP5490696B2 (en) Monoclonal antibodies specific for hemagglutinin and neuraminidase from influenza virus H5 or N1 subtypes and their use
Lu et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F (ab') 2 in mice
Carter et al. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus
CA2790949C (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
JP5597128B2 (en) H5 subtype-specific binding protein useful for diagnosis and monitoring of H5 avian influenza
CN104011077B (en) From the binding molecule with influenza A virus neutralization activity that human B cell is produced
JP5490695B2 (en) Monoclonal antibodies specific for hemagglutinin from influenza virus H5 subtype and uses thereof
Rosendahl Huber et al. Synthetic long peptide influenza vaccine containing conserved T and B cell epitopes reduces viral load in lungs of mice and ferrets
Rajao et al. Heterologous challenge in the presence of maternally-derived antibodies results in vaccine-associated enhanced respiratory disease in weaned piglets
JP5827701B2 (en) Immunodetection method for influenza virus H5 subtype
Kim et al. Vaccine efficacy of inactivated, chimeric hemagglutinin H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy
JP2008196967A (en) Influenza virus h5 subtype immunoassay
Adachi et al. Development of neutralization antibodies against highly pathogenic H5N1 avian influenza virus using ostrich (Struthio camelus) yolk
Qi et al. Seroprevalence of avian origin H3N2 canine influenza virus infection in pet dogs in Shenzhen, China
Cho et al. Detection of antibodies to equine arteritis virus by a monoclonal antibody-based blocking ELISA.
CN102241768B (en) Antibody against hemagglutinin of influenza A H1N1 virus
CN115947835B (en) Antibody targeting influenza B virus nucleoprotein and application thereof
Huang et al. Different neutralization efficiency of neutralizing monoclonal antibodies against avian influenza H5N1 virus to virus strains from different hosts
CN106771173A (en) The monoclonal antibody of anti-H9 subtype avian influenza virus, hybridoma cell strain and its application
Adachi et al. Ostrich produce cross-reactive neutralization antibodies against pandemic influenza virus A/H1N1 following immunization with a seasonal influenza vaccine
TWI418786B (en) Monoclonal antibody against hemagglutinin of avian influenza viruses subtype h6n1 and methods of making and using same
CN115819566B (en) Antibody targeting influenza A virus nucleoprotein and application thereof
CN115724959B (en) Antibody targeting influenza A virus nucleoprotein and application thereof
Salvi et al. Validation of indirect ELISA for quantitative testing of rabies antibodies during production of antirabies serum using equines